keyword
MENU ▼
Read by QxMD icon Read
search

avogaro

keyword
https://www.readbyqxmd.com/read/28188583/the-role-of-point-of-care-3-hydroxybutyrate-testing-in-patients-with-type-2-diabetes-undergoing-coronary-angiography
#1
S Vigili de Kreutzenberg, A Avogaro
PURPOSE: Ketone bodies, 3-hydroxybutyrate (3BOHB), and acetoacetate derive from increased free fatty acid beta-oxidation, thus reflecting marked insulin deprivation with or without decompensated diabetes. Objectives of this study were (1) to determine circulating levels of 3BOHB in patients with and without type 2 diabetes (T2DM), before and after an elective coronary angiography; (2) to detect 3BOHB modification during the procedure; (3) to study possible associations between 3BOHB and clinical parameters/outcomes...
February 11, 2017: Journal of Endocrinological Investigation
https://www.readbyqxmd.com/read/28183314/dpp-4-inhibition-has-no-acute-effect-on-bnp-and-its-n-terminal-pro-hormone-measured-by-commercial-immune-assays-a-randomized-cross-over-trial-in-patients-with-type-2-diabetes
#2
Gian Paolo Fadini, Benedetta Maria Bonora, Mattia Albiero, Martina Zaninotto, Mario Plebani, Angelo Avogaro
BACKGROUND: Use of dipeptidyl peptidase-4 inhibitors (DPP4-i) for the treatment of type 2 diabetes (T2D) has been associated with a possible increase in the risk for heart failure (HF). B-type natriuretic peptide (BNP), which is both a biomarker of HF and a hemodynamically active hormone, is a substrate of DPP-4. We herein tested the acute effects of the DPP-4i linagliptin on BNP and NT-proBNP in a cross-over placebo-controlled trial in patients with T2D with and without chronic kidney disease (CKD)...
February 10, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28151516/-cardiovascular-disease-in-diabetic-patients-risk-factors-clinical-history-and-prevention
#3
Angelo Avogaro
Cardiovascular disease (CVD) is the leading cause of death in patients with diabetes mellitus (DM) in which there is a rapid evolution and widespread early atherosclerosis, whose causes are manifold. In the presence of hyperglycemia there is the activation of multiple signaling responses involving, first endothelial activation and later dysfunction, which are the first detectable step toward the atherosclerotic disease. A healthy lifestyle is the cornerstone for the prevention and control of CVD in patients with DM, in whom we must pursue the control, not only of blood sugar levels, but also of all risk factors for CVD...
December 2016: Giornale Italiano di Cardiologia
https://www.readbyqxmd.com/read/28145047/influence-of-health-locus-of-control-and-fear-of-hypoglycaemia-on-glycaemic-control-and-treatment-satisfaction-in-people-with-type-1-diabetes-on-insulin-pump-therapy
#4
L Indelicato, V Mariano, S Galasso, F Boscari, E Cipponeri, C Negri, A Frigo, A Avogaro, E Bonora, M Trombetta, D Bruttomesso
AIM: To assess the influence of health locus of control and fear of hypoglycaemia on metabolic control and treatment satisfaction in people with Type 1 diabetes mellitus on continuous subcutaneous insulin infusion. METHODS: People with Type 1 diabetes on continuous subcutaneous insulin infusion for at least 1 year, sub-classified as an 'acceptable glucose control' group [HbA1c ≤58 mmol/mol (7.5%)] and a 'suboptimum glucose control' group [HbA1c >58 mmol/mol (7...
February 1, 2017: Diabetic Medicine: a Journal of the British Diabetic Association
https://www.readbyqxmd.com/read/28117343/selection-of-reference-genes-is-critical-for-mirna-expression-analysis-in-human-cardiac-tissue-a-focus-on-atrial-fibrillation
#5
Michela Masè, Margherita Grasso, Laura Avogaro, Elvira D'Amato, Francesco Tessarolo, Angelo Graffigna, Michela Alessandra Denti, Flavia Ravelli
MicroRNAs (miRNAs) are emerging as key regulators of complex biological processes in several cardiovascular diseases, including atrial fibrillation (AF). Reverse transcription-quantitative polymerase chain reaction is a powerful technique to quantitatively assess miRNA expression profile, but reliable results depend on proper data normalization by suitable reference genes. Despite the increasing number of studies assessing miRNAs in cardiac disease, no consensus on the best reference genes has been reached...
January 24, 2017: Scientific Reports
https://www.readbyqxmd.com/read/27982707/feasibility-of-long-term-closed-loop-control-a-multicenter-6-month-trial-of-24-7-automated-insulin-delivery
#6
Boris Kovatchev, Peiyao Cheng, Stacey M Anderson, Jordan E Pinsker, Federico Boscari, Bruce A Buckingham, Francis J Doyle, Korey K Hood, Sue A Brown, Marc D Breton, Daniel Chernavvsky, Wendy C Bevier, Paige K Bradley, Daniela Bruttomesso, Simone Del Favero, Roberta Calore, Claudio Cobelli, Angelo Avogaro, Trang T Ly, Satya Shanmugham, Eyal Dassau, Craig Kollman, John W Lum, Roy W Beck
BACKGROUND: In the past few years, the artificial pancreas-the commonly accepted term for closed-loop control (CLC) of blood glucose in diabetes-has become a hot topic in research and technology development. In the summer of 2014, we initiated a 6-month trial evaluating the safety of 24/7 CLC during free-living conditions. RESEARCH DESIGN AND METHODS: Following an initial 1-month Phase 1, 14 individuals (10 males/4 females) with type 1 diabetes at three clinical centers in the United States and one in Italy continued with a 5-month Phase 2, which included 24/7 CLC using the wireless portable Diabetes Assistant (DiAs) developed at the University of Virginia Center for Diabetes Technology...
January 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27900571/erratum-to-simvastatin-rapidly-and-reversibly-inhibits-insulin-secretion-in-intact-single-islet-cultures
#7
Valentina Scattolini, Camilla Luni, Alessandro Zambon, Silvia Galvanin, Onelia Gagliano, Catalin Dacian Ciubotaru, Angelo Avogaro, Fabio Mammano, Nicola Elvassore, Gian Paolo Fadini
No abstract text is available yet for this article.
February 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/27830474/simvastatin-rapidly-and-reversibly-inhibits-insulin-secretion-in-intact-single-islet-cultures
#8
Valentina Scattolini, Camilla Luni, Alessandro Zambon, Silvia Galvanin, Onelia Gagliano, Catalin Dacian Ciubotaru, Angelo Avogaro, Fabio Mammano, Nicola Elvassore, Gian Paolo Fadini
INTRODUCTION: Epidemiological studies suggest that statins may promote the development or exacerbation of diabetes, but whether this occurs through inhibition of insulin secretion is unclear. This lack of understanding is partly due to the cellular models used to explore this phenomenon (cell lines or pooled islets), which are non-physiologic and have limited clinical transferability. METHODS: Here, we study the effect of simvastatin on insulin secretion using single-islet cultures, an optimal compromise between biological observability and physiologic fidelity...
December 2016: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/27815289/long-term-prediction-of-cardiovascular-outcomes-by-circulating-cd34-and-cd34-cd133-stem-cells-in-patients-with-type-2-diabetes
#9
Gian Paolo Fadini, Mauro Rigato, Roberta Cappellari, Benedetta Maria Bonora, Angelo Avogaro
OBJECTIVE: Cardiovascular risk varies substantially in the population with diabetes, and biomarkers can improve risk stratification. Circulating stem cells predict future cardiovascular events and death, but data for the population with diabetes are scant. In this study we evaluated the ability of circulating stem cell levels to predict future cardiovascular outcomes and improve risk discrimination in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A cohort of 187 patients with type 2 diabetes was monitored for a median of 6...
January 2017: Diabetes Care
https://www.readbyqxmd.com/read/27696520/psychological-outcomes-of-evening-and-night-closed-loop-insulin-delivery-under-free-living-conditions-in-people-with-type-1-diabetes-a-2-month-randomized-crossover-trial
#10
J Kropff, J DeJong, S Del Favero, J Place, M Messori, B Coestier, A Farret, F Boscari, S Galasso, A Avogaro, D Bruttomesso, C Cobelli, E Renard, L Magni, J H DeVries
AIM: To assess the impact on fear of hypoglycaemia and treatment satisfaction with an artificial pancreas system used for 2 consecutive months, as well as participant acceptance of the artificial pancreas system. METHODS: In a randomized crossover trial patient-related outcomes associated with an evening-and-night artificial pancreas and sensor-augmented pump therapy were compared. Both intervention periods lasted 8 weeks. The artificial pancreas acceptance questionnaire (range 0-90, higher scores better), Hypoglycaemia Fear Survey II (range 0-72, higher scores worse) and Diabetes Treatment Satisfaction Questionnaire (range 0-36, higher scores better) were completed by 32 participants...
February 2017: Diabetic Medicine: a Journal of the British Diabetic Association
https://www.readbyqxmd.com/read/27696500/the-rs2274911-polymorphism-in-gprc6a-gene-is-associated-with-insulin-resistance-in-normal-weight-and-obese-subjects
#11
Andrea Di Nisio, Maria Santa Rocca, Gian Paolo Fadini, Luca De Toni, Giorgio Marcuzzo, Maria Cristina Marescotti, Marta Sanna, Mario Plebani, Roberto Vettor, Angelo Avogaro, Carlo Foresta
OBJECTIVE: Identification of the novel endocrine role of osteocalcin (OC) and its receptor GPRC6A has given rise to a new branch of research in OC/GPRC6A axis related to glucose metabolism. GPRC6A- and OC-deficient mice share features of the metabolic syndrome, in addition to male infertility. Recently, the polymorphism rs2274911 in GPRC6A was shown to be associated with testicular impairment. We aimed to investigate the role of rs2274911 polymorphism in glucose and lipid metabolism in a cohort of normal weight and obese subjects DESIGN, PATIENTS, SETTINGS: A total of 392 male and females, including 218 obese patients and 174 age-matched normal weight controls, were retrospectively selected...
October 1, 2016: Clinical Endocrinology
https://www.readbyqxmd.com/read/27632533/altered-emg-patterns-in-diabetic-neuropathic-and-not-neuropathic-patients-during-step-ascending-and-descending
#12
Fabiola Spolaor, Zimi Sawacha, Gabriella Guarneri, Silvia Del Din, Angelo Avogaro, Claudio Cobelli
Diabetic peripheral neuropathy (DPN) causes motor control alterations during daily life activities. Tripping during walking or stair climbing is the predominant cause of falls in the elderly subjects with DPN and without (NoDPN). Surface Electromyography (sEMG) has been shown to be a valid tool for detecting alterations of motor functions in subjects with DPN. This study aims at investigating the presence of functional alterations in diabetic subjects during stair climbing and at exploring the relationship between altered muscle activation and temporal parameter...
December 2016: Journal of Electromyography and Kinesiology
https://www.readbyqxmd.com/read/27618501/switching-from-twice-daily-glargine-or-detemir-to-once-daily-degludec-improves-glucose-control-in-type-1-diabetes-an-observational-study
#13
S Galasso, A Facchinetti, B M Bonora, V Mariano, F Boscari, E Cipponeri, A Maran, A Avogaro, G P Fadini, D Bruttomesso
BACKGROUND AND AIMS: Degludec is an ultralong-acting insulin analogue with a flat and reproducible pharmacodynamic profile. As some patients with type 1 diabetes (T1D) fail to achieve 24-h coverage with glargine or detemir despite twice-daily injections, we studied the effect of switching T1D patients from twice-daily glargine or detemir to degludec. METHODS AND RESULTS: In this prospective observational study, T1D patients on twice-daily glargine or detemir were enrolled...
December 2016: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://www.readbyqxmd.com/read/27514514/continued-efforts-to-translate-diabetes-cardiovascular-outcome-trials-into-clinical-practice
#14
REVIEW
Angelo Avogaro, Gian Paolo Fadini, Giorgio Sesti, Enzo Bonora, Stefano Del Prato
Diabetic patients suffer from a high rate of cardiovascular events and such risk increases with HbA1c. However, lowering HbA1c does not appear to yield the same benefit on macrovascular endpoints, as observed for microvascular endpoints. As the number of glucose-lowering medications increases, clinicians have to consider several open questions in the management of type 2 diabetes, one of which is the cardiovascular risk profile of each regimen. Recent placebo-controlled cardiovascular outcome trials (CVOTs) have responded to some of these questions, but careful interpretation is needed...
11, 2016: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/27440833/analyses-of-results-from-cardiovascular-safety-trials-with-dpp-4-inhibitors-cardiovascular-outcomes-predefined-safety-outcomes-and-pooled-analysis-and-meta-analysis
#15
REVIEW
Edoardo Mannucci, Ofri Mosenzon, Angelo Avogaro
The U.S. Food and Drug Administration requires that the cardiovascular (CV) safety of all new drugs for diabetes be demonstrated through pooled analyses of phase III studies or specifically designed trials. This requirement prompted several placebo-controlled, noninferiority CV safety trials in high-risk patients; to date, all completed trials showed that dipeptidyl peptidase (DPP)-4 inhibitors do not increase or reduce the risk of major CV events. These results apparently contrast with those of pooled analyses and meta-analyses of previous, smaller trials with metabolic end points, which had suggested a reduction of risk...
August 2016: Diabetes Care
https://www.readbyqxmd.com/read/27255499/plerixafor-improves-the-endothelial-health-balance-the-effect-of-diabetes-analysed-by-polychromatic-flow-cytometry
#16
Roberta Cappellari, Marianna D'Anna, Angelo Avogaro, Gian Paolo Fadini
BACKGROUND AND AIMS: Diabetes damages the endothelium and reduces the availability of bone marrow (BM)-derived endothelial progenitor cells (EPCs). The mobilization of hematopoietic stem cells (HSCs) and EPCs in response to G-CSF is impaired by diabetes, owing to CXCL12 dysregulation. We have previously shown that the CXCR4/CXCL12 disruptor plerixafor rescues HSC and EPC mobilization in diabetes. We herein explored the effects of plerixafor on HSCs, EPCs, and circulating endothelial cells (CECs) in patients with and without diabetes...
August 2016: Atherosclerosis
https://www.readbyqxmd.com/read/27208335/randomized-summer-camp-crossover-trial-in-5-to-9-year-old-children-outpatient-wearable-artificial-pancreas-is-feasible-and-safe
#17
Simone Del Favero, Federico Boscari, Mirko Messori, Ivana Rabbone, Riccardo Bonfanti, Alberto Sabbion, Dario Iafusco, Riccardo Schiaffini, Roberto Visentin, Roberta Calore, Yenny Leal Moncada, Silvia Galasso, Alfonso Galderisi, Valeria Vallone, Federico Di Palma, Eleonora Losiouk, Giordano Lanzola, Davide Tinti, Andrea Rigamonti, Marco Marigliano, Angela Zanfardino, Novella Rapini, Angelo Avogaro, Daniel Chernavvsky, Lalo Magni, Claudio Cobelli, Daniela Bruttomesso
OBJECTIVE: The Pediatric Artificial Pancreas (PedArPan) project tested a children-specific version of the modular model predictive control (MMPC) algorithm in 5- to 9-year-old children during a camp. RESEARCH DESIGN AND METHODS: A total of 30 children, 5- to 9-years old, with type 1 diabetes completed an outpatient, open-label, randomized, crossover trial. Three days with an artificial pancreas (AP) were compared with three days of parent-managed sensor-augmented pump (SAP)...
July 2016: Diabetes Care
https://www.readbyqxmd.com/read/27208331/day-and-night-closed-loop-glucose-control-in-patients-with-type-1-diabetes-under-free-living-conditions-results-of-a-single-arm-1-month-experience-compared-with-a-previously-reported-feasibility-study-of-evening-and-night-at-home
#18
Eric Renard, Anne Farret, Jort Kropff, Daniela Bruttomesso, Mirko Messori, Jerome Place, Roberto Visentin, Roberta Calore, Chiara Toffanin, Federico Di Palma, Giordano Lanzola, Paolo Magni, Federico Boscari, Silvia Galasso, Angelo Avogaro, Patrick Keith-Hynes, Boris Kovatchev, Simone Del Favero, Claudio Cobelli, Lalo Magni, J Hans DeVries
OBJECTIVE: After testing of a wearable artificial pancreas (AP) during evening and night (E/N-AP) under free-living conditions in patients with type 1 diabetes (T1D), we investigated AP during day and night (D/N-AP) for 1 month. RESEARCH DESIGN AND METHODS: Twenty adult patients with T1D who completed a previous randomized crossover study comparing 2-month E/N-AP versus 2-month sensor augmented pump (SAP) volunteered for 1-month D/N-AP nonrandomized extension. AP was executed by a model predictive control algorithm run by a modified smartphone wirelessly connected to a continuous glucose monitor (CGM) and insulin pump...
July 2016: Diabetes Care
https://www.readbyqxmd.com/read/27208316/multinational-home-use-of-closed-loop-control-is-safe-and-effective
#19
Stacey M Anderson, Dan Raghinaru, Jordan E Pinsker, Federico Boscari, Eric Renard, Bruce A Buckingham, Revital Nimri, Francis J Doyle, Sue A Brown, Patrick Keith-Hynes, Marc D Breton, Daniel Chernavvsky, Wendy C Bevier, Paige K Bradley, Daniela Bruttomesso, Simone Del Favero, Roberta Calore, Claudio Cobelli, Angelo Avogaro, Anne Farret, Jerome Place, Trang T Ly, Satya Shanmugham, Moshe Phillip, Eyal Dassau, Isuru S Dasanayake, Craig Kollman, John W Lum, Roy W Beck, Boris Kovatchev
OBJECTIVE: To evaluate the efficacy of a portable, wearable, wireless artificial pancreas system (the Diabetes Assistant [DiAs] running the Unified Safety System) on glucose control at home in overnight-only and 24/7 closed-loop control (CLC) modes in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS: At six clinical centers in four countries, 30 participants 18-66 years old with type 1 diabetes (43% female, 96% non-Hispanic white, median type 1 diabetes duration 19 years, median A1C 7...
July 2016: Diabetes Care
https://www.readbyqxmd.com/read/27093207/-treatment-of-patients-with-type-2-diabetes-mellitus-cardiovascular-safety-of-incretin-based-therapy-supported-by-the-elixa-and-tecos-trials
#20
Angelo Avogaro
The risk of morbidity and mortality from cardiovascular disease in patients with type 2 diabetes is about 2-fold higher compared to their non-diabetic counterparts. In December 2008, the Food and Drug Administration published guidelines for the evaluation of cardiovascular risk in new antidiabetic therapies. A shift of emphasis occurred from short-term glycated hemoglobin-centered trials to trials testing cardiovascular safety. The SAVOR-TIMI 53 and the EXAMINE trials with the dipeptidyl peptidase 4 (DPP-4) inhibitors saxagliptin and alogliptin were cardiovascular neutral...
April 2016: Giornale Italiano di Cardiologia
keyword
keyword
94325
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"